Duopharma Biotech Bhd
Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as ca… Read more
Duopharma Biotech Bhd - Asset Resilience Ratio
Duopharma Biotech Bhd (7148) has an Asset Resilience Ratio of 18.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Duopharma Biotech Bhd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Duopharma Biotech Bhd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM268.67 Million | 18.52% |
| Short-term Investments | RM0.00 | 0% |
| Total Liquid Assets | RM268.67 Million | 18.52% |
Asset Resilience Insights
- Good Liquidity Position: Duopharma Biotech Bhd maintains a healthy 18.52% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Duopharma Biotech Bhd Industry Peers by Asset Resilience Ratio
Compare Duopharma Biotech Bhd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Duopharma Biotech Bhd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Duopharma Biotech Bhd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.71% | RM161.25 Million | RM1.38 Billion | -12.35pp |
| 2023-12-31 | 24.06% | RM323.59 Million | RM1.35 Billion | +17.71pp |
| 2022-12-31 | 6.34% | RM77.49 Million | RM1.22 Billion | +3.73pp |
| 2021-12-31 | 2.62% | RM30.45 Million | RM1.16 Billion | -2.37pp |
| 2020-12-31 | 4.99% | RM52.81 Million | RM1.06 Billion | +0.46pp |
| 2019-12-31 | 4.53% | RM41.67 Million | RM919.80 Million | +1.94pp |
| 2018-12-31 | 2.59% | RM21.70 Million | RM836.38 Million | -4.33pp |
| 2017-12-31 | 6.93% | RM48.86 Million | RM705.24 Million | -5.84pp |
| 2016-12-31 | 12.77% | RM84.48 Million | RM661.46 Million | -- |